The Administrative Core (AdminCore) will be established as an integrated, priority-setting consortium involving multiple participating institutions with collaborative programmatic involvement from NIAID with the PD to advance the science and enhance potential product outcome. The operations and management function is designed to provide administrative support that facilitates scientific collaborations and efficient use of resources. To best serve the interest of the Center, the AdminCore will be centralized at the Public Health Research Institute of New Jersey Medical School-UMDNJ. The AdminCore will be overseen by the Center PD, who will be supported by a program administrator (50% FTE) and a financial director (15% FTE) to coordinate and manage all administrative support functions. To support the Center objectives, the AdminCore will organize regular meetings ofthe investigators, their collaborators (and subcontractors) and Scientific Cores. In addition the AdminCore will arrange for meetings ofthe Executive Committee and the annual meeting of the External Scientific Advisory Committee. The AdminCore will produce and submit the annual progress report to the NIH, and will coordinate research publications, meeting presentations of study results and any logistics related to travel. The CETR Administrative Core will have the following Specific Aims:1. To establish a highly efficient operations and management structur that provides essential oversight, guidance and support services to the CETR Program Leaders and integrates a Scientific Advisory Committee and the NIAID Program representative as strategic advisors. 2. To promote the flow of information, prioritization of compound development, and resource allocations by supporting regular reviews, and to manage regulatory issues and the preparation of interim and year-end reports. 3. To establish a product development strategy that addresses logistics for intellectual property filings and licensing opportunities and negotiations. 4. To coordinate publications and presentations of results arising from these studies.

Public Health Relevance

The Administration Core will provide oversight and guidance for the entire conduct ofthe CETR program by addressing all logistics related to the Program, fostering communication between multiple Program Leaders, Core directors, the Scientific Advisory Committee and the NIAID program officer. It will establish working priorities, objective reviews, and promote business development activities to support the Center goals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109713-01
Application #
8655932
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-04-25
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
DUNS #
City
Newark
State
NJ
Country
United States
Zip Code
07103
Kumar, Pradeep; Capodagli, Glenn C; Awasthi, Divya et al. (2018) Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. MBio 9:
Nukaga, Michiyoshi; Papp-Wallace, Krisztina M; Hoshino, Tyuji et al. (2018) Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam. Antimicrob Agents Chemother 62:
Becka, Scott A; Zeiser, Elise T; Marshall, Steven H et al. (2018) Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans. Diagn Microbiol Infect Dis 92:253-258
Vila-Farres, Xavier; Chu, John; Ternei, Melinda A et al. (2018) An Optimized Synthetic-Bioinformatic Natural Product Antibiotic Sterilizes Multidrug-Resistant Acinetobacter baumannii-Infected Wounds. mSphere 3:
Papp-Wallace, Krisztina M; Barnes, Melissa D; Alsop, Jim et al. (2018) Relebactam Is a Potent Inhibitor of the KPC-2 ?-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 62:
Lane, Thomas; Russo, Daniel P; Zorn, Kimberley M et al. (2018) Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Mol Pharm 15:4346-4360
Papp-Wallace, Krisztina M; Nguyen, Nhu Q; Jacobs, Michael R et al. (2018) Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using ?-Lactamase Inhibitors and ?-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem 61:4067-4086
Lin, Wei; Das, Kalyan; Degen, David et al. (2018) Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). Mol Cell 70:60-71.e15
Inoyama, Daigo; Paget, Steven D; Russo, Riccardo et al. (2018) Novel Pyrimidines as Antitubercular Agents. Antimicrob Agents Chemother 62:
Becka, Scott A; Zeiser, Elise T; Barnes, Melissa D et al. (2018) Characterization of the AmpC ?-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother 62:

Showing the most recent 10 out of 23 publications